April 3, 2024Open Access

Real‐world persistence of multiple sclerosis disease‐modifying therapies

Key Points

Key points are not available for this paper at this time.

Abstract

Treatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real-world rates of persistence on disease-modifying therapies (DMTs) for people with multiple sclerosis (pwMS) and reasons for DMT discontinuation.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Tallantyre et al. (Wed,) studied this question.

synapsesocial.com/papers/68e708c0b6db643587682074 https://doi.org/https://doi.org/10.1111/ene.16289

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: YES2022 · 9 citations
2Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis2020 · 20 citations
3A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies2019 · 26 citations
4Comparative effectiveness of teriflunomide and dimethyl fumarate2019 · 45 citations
5Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy2020 · 1 citations

Demander à l'IA

Bookmark

View Full Paper